Ontology highlight
ABSTRACT: Background
Most commercial foot-and-mouth disease (FMD) vaccines have various disadvantages, such as low antibody titers, short-lived effects, compromised host defense, and questionable safety.Objectives
To address these shortcomings, we present a novel FMD vaccine containing Dectin-1 agonist, β-D-glucan, as an immunomodulatory adjuvant. The proposed vaccine was developed to effectively coordinate innate and adaptive immunity for potent host defense against viral infection.Methods
We demonstrated β-D-glucan mediated innate and adaptive immune responses in mice and pigs in vitro and in vivo. The expressions of pattern recognition receptors, cytokines, transcription factors, and co-stimulatory molecules were promoted via FMD vaccine containing β-D-glucan.Results
β-D-glucan elicited a robust cellular immune response and early, mid-, and long-term immunity. Moreover, it exhibited potent host defense by modulating host's innate and adaptive immunity.Conclusion
Our study provides a promising approach to overcoming the limitations of conventional FMD vaccines. Based on the proposed vaccine's safety and efficacy, it represents a breakthrough among next-generation FMD vaccines.
SUBMITTER: Kim HW
PROVIDER: S-EPMC10272586 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature
Kim Hyeong Won HW Ko Mi-Kyeong MK Park So Hui SH Hwang Seong Yun SY Kim Dong Hyeon DH Park Sun Young SY Ko Young-Joon YJ Kim Su-Mi SM Park Jong-Hyeon JH Lee Min Ja MJ
Frontiers in immunology 20230602
<h4>Background</h4>Most commercial foot-and-mouth disease (FMD) vaccines have various disadvantages, such as low antibody titers, short-lived effects, compromised host defense, and questionable safety.<h4>Objectives</h4>To address these shortcomings, we present a novel FMD vaccine containing Dectin-1 agonist, β-D-glucan, as an immunomodulatory adjuvant. The proposed vaccine was developed to effectively coordinate innate and adaptive immunity for potent host defense against viral infection.<h4>Me ...[more]